Journal: The New England journal of medicine
The publication discusses recent advancements in targeted therapies for non-small cell lung cancer (NSCLC).
It highlights outcomes from clinical trials evaluating the efficacy and safety of novel agents aimed at specific genetic mutations driving tumor growth.
The article underscores the importance of molecular profiling in selecting appropriate treatments to improve patient prognosis and reduce adverse effects.
Overall, it emphasizes a shift toward personalized medicine in oncology, driven by a deeper understanding of tumor biology and resistance mechanisms.